Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: One-year randomised multicentre trial

Digestive and Liver Disease

Volumn 34, Issue 11, 2002, Pages 787-793

  Paoluzi, P ^h   D'Albasio, G ^a   Pera, A ^b   Bianchi Porro, G ^c   Paoluzi, O A ⁱ   Pica, R ⁱ   Cottone, M ^d   Miglioli, M ^e   Prantera, C ^f   Sturniolo, G ^g   Ardizzone, S ^c  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^g Department of Medical Oncology   (Italy)

^h Dipto di Sci Clin (Endocrinol)   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

5 aminosalicylic acid; Mesalazine; Ulcerative colitis

Indexed keywords

CORTICOSTEROID DERIVATIVE; ENEMA; IMMUNOSUPPRESSIVE AGENT; MESALAZINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; FURUNCULOSIS; GASTROINTESTINAL ENDOSCOPY; HISTOLOGY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; STATISTICAL ANALYSIS; STRATIFICATION; SUPPOSITORY; TABLET FORMULATION; ULCERATIVE COLITIS;

EID: 12244289249     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80072-X     Document Type: Article

References (29)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
2. Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the therapeutic moiety of sulphasalazine. Gut 1980;21:632-5.
3. Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, et al. Treatment of ulcerative colitis with high dose 5-aminosalicylic acid enemas. Lancet 1981;ii:270-1.
4. Sutherland LR, Martin F. 5-Aminosalicylic acid enema in treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987;92:1894-8.
5. Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993;38:1843-50.
6. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991;32:929-31.
7. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tampieri M, Iannone P, et al. Topical treatment with 5-aminosalicylic acid in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. Int J Colorectal Dis 1990;5:79-81.
8. Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990;25:663-8.
9. Williams CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99-Tc-labeled 5-ASA suppositories. Dig Dis Sci 1987;32:S71-5.
10. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tabanelli GM, Miglioli M, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 1988;10:406-9.
11. D'Albasio G, Paoluzi P, Campieri M, Bianchi Porro G, Pera A, Prantera C, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998;93:799-803.
12. Campieri M, Lanfranchi GA, Brignola C, Bazzocchi G, Gionchetti P, Minguzzi MR, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986;29:108-10.
13. Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, Di Febo G, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992;37:1890-7.
14. Qasim A, Seery J, O'Morain CA. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. Digest Liver Dis 2001;33:393-8.
15. Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, et al. Mesalazine foam (Salofalk® foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk® enema. Ital J Gastroenterol Hepatol 1999;31:677-84.
16. Sutherland LR, May GR, Eldon AS. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-9.
17. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993;88:1188-97.
18. The Rowasa Study Group. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Gastroenterology 1995;108:A909.
19. Hanauer SB. Dose-ranging of mesalamine (PENTASA) enemas in the treatment of acute ulcerative colitis proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis 1998;4:79-83.
20. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutical trial. Br Med J 1955;ii:1041-8.
21. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964;1:89-92.
22. Truelove SC, Richard WCD. Biopsy studies in ulcerative colitis. Br Med J 1956;1:1315-8.
23. Bianchi Porro G, Ardizzone S, Petrillo M, Fasoli A, Molteni P, Imbesi V. Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study. Am J Gastroenterol 1995;90:736-9.
24. Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:557-62.
25. Biddle WL, Miner PB Jr. Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990;99:113-8.
26. Mehta RP. Acute interstitial nephritis due to 5-aminosalicylic acid. Can Med Assoc J 1990;143:1031-2.
27. Barry M. Mesalazine and renal impairment. Prescribers' Journal 1992;32:205-9.
28. Thuluvath PJ, Ninkovic M, Calam J, Anderson M. Mesalazine-induced interstitial nephritis. Gut 1994;35:1493-6.
29. Di Paolo MC, Paoluzi OA, Pica R, Iacopini F, Crispino P, Rivera M, et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. Digest Liver Dis 2001;33:563-9.